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¶Departament de Química, Universitat Autoǹoma de Barcelona, Cerdanyola del Valles̀, 08193 Barcelona, Spain
ψInstitucio ́ Catalana de Recerca i Estudis Avanca̧ts (ICREA), 08010 Barcelona, Spain
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ABSTRACT: The adenosinergic system operates through G
protein-coupled adenosine receptors, which have become
promising therapeutic targets for a wide range of pathological
conditions. However, the ubiquity of adenosine receptors and
the eventual lack of selectivity of adenosine-based drugs have
frequently diminished their therapeutic potential. Accordingly,
here we aimed to develop a new generation of light-switchable
adenosine receptor ligands that change their intrinsic activity
upon irradiation, thus allowing the spatiotemporal control of
receptor functioning (i.e., receptor activation/inactivation
dependent on location and timing). Therefore, we synthesized
an orthosteric, photoisomerizable, and nonselective adenosine
receptor agonist, nucleoside derivative MRS5543 containing
an aryl diazo linkage on the N6 substituent, which in the dark (relaxed isomer) behaved as a full adenosine A3 receptor (A3R) and
partial adenosine A2A receptor (A2AR) agonist. Conversely, upon photoisomerization with blue light (460 nm), it remained a full
A3R agonist but became an A2AR antagonist. Interestingly, molecular modeling suggested that structural diﬀerences encountered
within the third extracellular loop of each receptor could modulate the intrinsic, receptor subtype-dependent, activity. Overall, the
development of adenosine receptor ligands with photoswitchable activity expands the pharmacological toolbox in support of
research and possibly opens new pharmacotherapeutic opportunities.
■ INTRODUCTION
Adenosine, a well-known neuromodulator,1 exerts its physio-
logical eﬀects through four subtypes (A1, A2A, A2B, and A3) of G
protein-coupled receptors (GPCRs).2 Agonists and antagonists
of adenosine receptors have an enormous therapeutic potential
for both peripheral and central diseases, including cerebral and
cardiac ischemic diseases, sleep disorders, immune and
inﬂammatory disorders, Parkinson’s disease, epilepsy, and
cancer.3 However, although medicinal chemistry for adenosine
receptors has been widely developed in recent decades, several
adenosine receptor ligands that entered clinical trials have
elicited undesirable side eﬀects precluding their further
development. Thus, the in vivo lack of drug selectivity may
lead to the inability of controlling receptor activity in time and
space. Interestingly, these kinds of drawbacks can be addressed
by means of photoisomerization, which for instance was used as
the basis to achieve temporal and local activation of biologically
active substances or their release from liposomes.4,5 Similarly,
aryl diazo derivatives were designed to interconvert between cis
and trans forms upon irradiation with UV-A light in order to
produce diﬀerential eﬀects on ion channels, such as potassium
channels.4,5 Azobenzene-based photoswitches have also been
used to control metabotropic glutamate receptors at their
orthosteric6 and allosteric7 sites. Overall, controlling drug
activity with light oﬀers the possibility of enhancing
pharmacological selectivity with spatiotemporal patterns of
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illumination, thus enabling localized drug eﬀects and the
application of dosing patterns.8
We now describe a photoswitchable aryl diazo derivative of a
potent but nonselective adenosine receptor agonist N6-2-(4-
aminophenyl)ethyladenosine (APNEA 1), termed MRS5543 2
(Figure 1), which functions as a photochromic adenosine
receptor ligand showing diﬀerential pharmacodynamics. The
design approach was based on the observation that the N6
region of adenosine agonists can accommodate diverse
substitutions without losing the ability to bind to the receptors,
while marked eﬀects on the pharmacological proﬁle, either
subtype selectivity or eﬃcacy at a given subtype, are observed
following relatively subtle structural changes of the N6
substituent.9 Interestingly, X-ray crystallographic analysis of
agonist- and antagonist-bound states of the A2AR indicated a
conformational reorganization of the second and third
extracellular loops (ELs) in an agonist-bound, active-like
state.8 Hydrophobic N6 substituents of adenosine receptor
agonists interact largely with these regions of the receptor.
Thus, we hypothesized that the introduction of a trans−cis
photoisomerizable azobenzene group fused with a sterically
bulky and extended N6 chain would have characteristic eﬀects
on the agonist proﬁle. Furthermore, in view of potential
physiological applications, the photochromic group of
MRS5543 was designed to present a red-shifted absorption
spectrum with respect to regular, violet-excitable azobenzene
and a short-lived cis state in aqueous medium that could rapidly
back-isomerize to the initial trans isomer in the absence of
illumination.10 Overall, here we aimed to demonstrate that
photoinduced diﬀerential pharmacological responses of this
compound could be attained using visible light and a single
irradiation source.11
■ RESULTS
MRS5543 Synthesis and Photochemical Character-
ization. The aryl diazo derivative MRS5543 was prepared from
commercially available APNEA and puriﬁed to homogeneity
using a modiﬁcation of previously reported methods.12 In brief,
the aryl amine of APNEA was diazotized and the resulting
diazonium salt coupled to p-(diethylamino)-benzene (Figure
1). Subsequently, we undertook the photochemical character-
ization of MRS5543 in solution. First, the steady-state
absorption spectra of this compound in DMSO and HBSS
were measured (Figure 2A). They present similar maxima at λ
= 430 (DMSO) and 460 nm (HBSS) arising from the well-
known π→ π* transition of its trans-azobenzene moiety, which
is bathochromically shifted with respect to violet-excitable,
regular azobenzenes owing to the diethylamino substituent
introduced.13 As such, trans → cis photoisomerization of
MRS5543 should take place under irradiation with blue-green
visible light. However, no azobenzene photoisomerization was
observed by steady-state UV−vis absorption spectroscopy upon
illumination at λexc = 420−460 nm in DMSO and HBSS. This
was ascribed to the short lifetime expected for the photo-
induced cis state of the compound due to the azobenzene
diethylamino substituent,11,13 which would therefore lead to
fast, spontaneous cis → trans back-isomerization in the dark.
Transient absorption measurements were conducted to
dissect this process. As shown in Figure 2, pulsed excitation
of MRS5543 at λexc = 460 nm in DMSO and HBSS resulted in
an immediate loss of trans state absorption at λ = 440 nm, thus
indicating the formation of the cis isomer of the switchable
molecule. Because of the lower extinction coeﬃcient of this
species within the 380−500 nm region with respect to the trans
state,11,13 the transient absorption spectra at t = 0 shows a large
negative bleaching signal that mirror-images the steady-state
absorption spectra of trans-MRS5543 (Figure 2B). Once
produced, the cis isomer of the compound rapidly returned
to the trans state via thermal back-isomerization, which allowed
the initial absorption at λ = 440 nm to be recovered in the
second (in DMSO) and subsecond (in HBSS) time scales, as
shown in Figure 2C,D. Thermal cis state lifetimes were
Figure 1. Synthesis of MRS5543, 2. The photocommutable nucleoside MRS5543 was synthesized in two steps using the nonselective adenosine
receptor agonist APNEA 1, an arylamine that could be readily diazotized without the use of protecting groups.
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determined from monoexponential ﬁts of the experimental
absorption recovery curves (τ = 430 and 0.70 ms in DMSO and
HBSS, respectively) and they were in agreement with those
reported for similar azobenzene systems in polar media.11,14
Such short lifetimes should enable photodriving the system
with a single irradiation source, since the photoinduced cis
molecules should immediately relax back to their trans state
when switching oﬀ the illumination.
Light-Mediated Modulation of MRS5543 Intrinsic
Activity. Once the capability of MRS5543 to photoisomerize
was demonstrated, we aimed to assess the ability of both cis and
trans isomers to modulate adenosine receptor functioning.
Since we used APNEA (a nonselective adenosine receptor
agonist initially used to characterize the A3R
15) as the chemical
template for the synthesis of MRS5543, it was necessary to
evaluate its intrinsic activity at this Gαi/o coupled adenosine
receptor subtype.16 Therefore, we assessed A3R-mediated
inhibition of adenylyl cyclase activity upon MRS5543 challenge
both in the dark (i.e., trans isomer) and during cis photo-
converting conditions (i.e., continuous 460 nm irradiation).
Both isomers of MRS5543 were equally able to inhibit
forskolin-induced cAMP accumulation to the same extent as
APNEA (Figure 3). Indeed, cis and trans MRS5543 showed
similar potency (EC50) and eﬃcacy (Emax) values in modulating
adenylyl cyclase activity in cells expressing A3R (Table 1), thus
suggesting that MRS5543 photoisomerization did not alter its
A3R agonist eﬃcacy.
Next, we aimed to study the intrinsic activity of MRS5543 at
a diﬀerent APNEA-sensitive adenosine receptor, the A2AR.
Thus, under the same experimental conditions MRS5543 dose-
dependently induced cAMP accumulation in dark conditions
(EC50 = 150 ± 50 nM) (Table 1), indicating a partial agonist
behavior when compared to APNEA-mediated full activation of
the A2AR (Figure 4, Table 1). Unexpectedly, when A2AR-
expressing cells were continuously irradiated at 460 nm (i.e., cis
photoconverting conditions), MRS5543 was unable to trigger
activation of the A2AR (Figure 4) (Table 1). Hence, these
results demonstrated that while the trans isomer partially
activated the A2AR, the cis isomer was inactive.
Subsequently, we aimed to elucidate the lack of intrinsic
activity of the cis MRS5543 isomer. Thus, the potential neutral
competitive antagonist activity of this molecule was evaluated.
To this end, the ability to compete with a prototypical,
orthosteric A2AR full agonist, 2-[p-(2-carboxyethyl)phenyl-
ethylamino]-5′-N-ethylcarboxamidoadenosine (CGS21680),
was assessed. Interestingly, when A2AR expressing cells were
challenged with CGS21680, cAMP accumulation was observed
under both dark and irradiating conditions (Figure 5). This
A2AR agonist intrinsic activity was blocked by 4-[2-[7-amino-2-
(2-furyl)-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethyl]-
phenol (ZM241385), a selective A2AR antagonist (Figure 5).
On the other hand, incubation of cells with CGS21680 plus
MRS5543 in the dark (i.e., trans MRS5543, partial agonist)
prompted a partial A2AR activation, while under cis photo-
converting conditions MRS5543 was able to completely block
CGS21680-mediated cAMP accumulation. These results
suggested that the trans MRS5543 (i.e., partial agonist) would
in fact act as a limited competitive A2AR antagonist in the
presence of a full agonist (i.e., CGS21680), thus reducing the
potency of CGS21680 with a concomitant net decrease in the
activation of the A2AR, and importantly conﬁrming that the cis-
isomer behaved purely as a competitive antagonist (Figure 5).
Overall, we concluded that both MRS5543 isomers showed
agonist activity at the A3R while the cis and trans isomers of
MRS5543 showed antagonist and partial agonist activity at the
A2AR, respectively.
Figure 2. Photochemical characterization of MRS5543. (A) Steady-
state absorption spectra of trans-MRS5543 (5 μM) in DMSO (blue)
and HBSS (red). (B) Transient absorption spectrum at t = 0 of trans-
MRS5543 (10 μM) upon pulsed excitation at λexc = 460 nm and 25 °C
(DMSO: blue; HBSS: red). (C,D) Variation of the absorption at λ =
440 nm of trans−cis mixtures of MRS5543 prepared by irradiation of
the intitial trans state (10 μM) with a single ns laser pulse (t = 0) at
λexc = 460 nm and 25 °C (C: DMSO; D: HBSS). Solid thick lines
correspond to monoexponential ﬁtting of the experimental data.
Figure 3. Eﬀect of MRS5543 in A3R-mediated cAMP accumulation.
HEK293 cells were transiently transfected with the human A3R and
the forskolin-stimulated cAMP production was measured in the
absence (basal) or presence of APNEA (20 nM), MRS5543 (20 nM),
or MRS5543 (200 nM) both in dark conditions (white column) and
upon irradiation at 460 nm (purple column). Data (means ± SEM of
triplicates) are given as percentage of the forskolin stimulated cells in
basal and dark conditions. No signiﬁcant diﬀerences were found when
dark vs 460 nm conditions were compared within each treatment
(two-way ANOVA with a Bonferroni posthoc test). N.S., not
signiﬁcant. Similar results were obtained in three independent
experiments.
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Molecular Modeling of MRS5543 Docking at Human
A3R and A2AR. The putative binding conformations of
MRS5543 cis and trans isomers in complex with A3R and
A2AR were evaluated through molecular modeling studies. In
particular, a recently reported agonist-bound human A2AR
crystallographic structure (PDB ID: 3QAK)17 and a homology
model of the human A3R,
18 built using this A2AR structure as a
template, were used to perform docking simulations of both
isomers. The multiply substituted agonist ligand present in this
A2AR crystal structure (6-(2,2-diphenylethylamino)-9-
((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetra-hydro-
furan-2-yl)-N-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)-
ethyl)-9H-purine-2-carboxamide, UK-432097) contained a
bulky N6 substituent, which displaced EL3 to open the binding
site and to allow recognition of other N6 substituted
nucleosides.
The docking poses of each MRS5543 isomer inside the A3R
and A2AR binding sites (Figure 6) preserved most of the main
receptor−ligand interactions of ribose and adenine moieties
Table 1. Half-Maximal-Eﬀective Concentration (EC50) Values and Maximum Responses (Emax) of APNEA and MRS5543
Modulating Adenylyl Cyclase Activity in Transfected HEK293 Cells Expressing the Indicated Adenosine Receptorb
bThe maximal eﬃcacy (Emax) of MRS5543 in modulating adenylyl cyclase activity through the A3R and A2AR is compared to that observed for
APNEA. Also, for each compound (i.e., APNEA and MRS5543) the impact of 460 nm irradiation into the EC50 and Emax was analyzed. N.D. non
determinable. aP < 0.05 vs APNEA.
Figure 4. MRS5543-dependent photomodulation of A2AR-mediated
cAMP accumulation. HEK293 cells were transiently transfected with
the human A2AR and the cAMP production was measured in the
absence or presence of increasing concentrations of MRS5543 both in
dark conditions (white circles) and upon irradiation at 460 nm (purple
circles). APNEA (1 μM) was used as a positive control of A2AR-
mediated cAMP accumulation. Data (means ± SEM of triplicates) are
given as fold over the basal activity. Similar results were obtained in
three independent experiments.
Figure 5. MRS5543 cis isomer blocks A2AR-mediated cAMP
accumulation. HEK293 cells were transiently transfected with the
human A2AR and the cAMP production was measured upon
stimulation with the A2AR agonist CGS21680 (500 nM) alone or in
the presence of ZM241385 (1 μM) or MRS5543 (3 μM) both in dark
conditions (white columns) and upon irradiation at 460 nm (purple
columns). Data (means ± SEM of triplicates) are given as percentage
of the CGS stimulated cells in dark conditions. The asterisks denote
data signiﬁcantly diﬀerent when dark vs 460 nm was compared. ***P
< 0.001, two-way ANOVA with a Bonferroni posthoc test. N.S., not
signiﬁcant. Similar results were obtained in three independent
experiments.
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observed in the agonist-bound A2AR crystal structures.
17,19 In
particular, the 3′- and 2′-hydroxyl groups formed H-bonds with
hydrophilic residues (using a GPCR numbering convention)20
at positions 7.42 (Ser277 in A2AR and Ser271 in A3R) and 7.43
(His278 in A2AR and His272 in A3R), respectively.
Furthermore, a threonine residue at position 3.36 (Thr88 in
A2AR and Thr94 in A3R) formed a H-bond with the 5′-
hydroxymethyl group of the ligand. The side chain of
asparagine 6.55 (Asn253 in A2AR and Asn250 in A3R) strongly
interacted with the compound through two H-bonds involving
the 6-amino group and the N7 atom of the adenine ring.
Moreover, the adenine core was anchored inside the binding
site by a π−π stacking interaction with a phenylalanine in EL2
(Phe168 in A2AR and Phe168 in A3R) and strong hydrophobic
contacts with leucine 6.51 (Leu249 in A2AR and Leu246 in
A3R) and isoleucine 7.39 (Ile274 in A2AR and Ile268 in A3R).
Even though the interactions formed by the two isomers with
the residues of the lower part of the ARs binding sites were very
similar, some diﬀerences were observed when considering the
interactions with the upper part of the cavity and the loop
region.
As shown in Figure 6, at both the A2AR and A3R, the N
6
substituent of the MRS5543 trans isomer was directed toward
the outside of the cavity, and it was predicted to make contact
with residues of EL2. However, no signiﬁcant diﬀerences were
seen in the interactions of MRS5543 with the two receptor
subtypes. In contrast, the N6-substituent of the cis isomer
impinged on top of the binding site entrance, and its
orientation and interactions were particular for each receptor
subtype, mainly due to diﬀerences in the residues present in the
upper region of the binding sites (Figure 6B,C). Interestingly,
at the A2AR structure, the distal p-diethylaminophenyl moiety
was able to ﬁt a subpocket located under EL3 and between
TM6 and TM7, delimited by Ile252 (6.54), Phe255 (6.57),
Thr256 (6.58), Pro260 (EL3), Cys262 (EL3), His264 (EL3),
Ala265 (EL3), and Met270 (7.35) (Figure 6C,E). On the other
hand, at the A3R structure there was no side pocket between
TM6 and TM7 able to accommodate the p-diethylaminophenyl
group (Figure 6B,D), and this determined a diﬀerent
orientation of the N6 substituent. This substituent was located
more external to the binding cavity and able to adopt diﬀerent
poses (Figure 6D).
In fact, as shown in Figure 6, the region around EL3 at the
A3R is narrower and not suitable to accommodate the N
6
substituent, as compared to that of the A2AR, which shows an
opening under the loop. This is mainly due to the fact that EL3
of the A3R is shorter (5 residues long) in comparison to EL3 of
the A2AR (8 residues long) (Figure 6A). Moreover, in the A2AR
EL3 presents a disulﬁde bridge (Cys259-Cys262), and two
proline residues that confer more rigidity to the loop and
potentially stabilize it in a conformation that leads to the
formation of the subpocket between TM6 and TM7.
Interestingly, mutagenesis studies at the A1R showed that
mutation of the two proline residues in EL3 aﬀects basal
activation levels and agonist potency at this subtype, suggesting
that rigidity in EL3 is an important feature in receptor
activation.21 Our previous study on a series of 4′-truncated
(N)-methanocarba-adenosine derivatives also highlighted the
importance of speciﬁc interactions of the N6-substituents with
the region located between TM6 and TM7 in determining
diﬀerent aﬃnity and selectivity proﬁles at ARs.18 Overall, some
diﬀerences were observed for the two MRS5543 isomers over
A3R and A2AR subtypes that could be related to structural
diﬀerences in the EL3 region of these receptors and its ability to
interact with the N6 substituent, thus having potential
implications for ligand binding and/or receptor activation.
■ DISCUSSION
The use of photoisomerizable receptor ligands was ﬁrst
designed for operating with fast ion channels,22−24 while its
application to GPCRs has been much more recent.6,7 Recently,
azobenzene moieties were incorporated into bioactive peptides
and cyclopeptides that act through GPCRs as conformational
probes to establish relationships with its bioactivity.25 Here, we
synthesized a chemically stable arylazo derivative MRS5543 of a
known nonselective adenosine receptor agonist as a pharmaco-
logical tool for probing the dependence on receptor aﬃnity and
eﬃcacy of conformational eﬀects, particularly by direct contact
with the extracellular regions of the receptor. Thus, we fused a
commonly used photoisomerizable azobenzene moiety to a
known GPCR pharmacophore, i.e., APNEA, with the expect-
ation that it would interact with conformationally sensitive
regions of adenosine receptors. The distal azobenzene moiety
that was fused also contained a p-diethylamino group that
increased the reactivity of this moiety toward diazonium salts
and the water solubility of the ﬁnal product, which was not
expected to prevent receptor binding. In addition, this
substituent also red-shifted the absorption spectrum of the
azobenzene unit and decreased the thermal stability of its cis
isomer, thus enabling operation of the system with visible light
and a single irradiation source. Importantly, the N6 moiety of
adenosine receptor agonists is known to be amenable to
extensive structural variation while retaining receptor inter-
actions. Moreover, this substituent class is known to associate
with a conformationally plastic and potentially functionally
Figure 6. MRS5543 docking at the human A3R homology model and
the human A2AR X-ray structure. (A) Sequence alignment of human
A2AR and human A3R. Sequence of EL3 is highlighted. A detailed view
of the region around EL3 of the A3R (B) and A2AR (C) is shown. The
Connolly surface of residues belonging to EL3 and to the upper parts
of TM6 and TM7 is displayed. Surface color indicates hydrophobic
regions (green), mildly polar regions (blue), and H-bonding regions
(magenta). The docking poses of MRS5543 trans and cis isomers (in
green) inside the binding site of the A3R (D) and A2AR (E) is shown.
Side chains of some amino acids important for ligand recognition and
H-bonding interactions are highlighted. Hydrogen atoms are not
displayed.
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important region of adenosine receptors. On the other hand,
we used an X-ray structure of the A2A receptor and a well-
validated homology model of the closely related A3 receptor to
predict diﬀerential interactions of cis and trans isomers. By
basing the design of MRS5543 on APNEA, it was possible to
achieve high aﬃnity of the diazo derivative at both A2A and A3
receptors.
Evidence is increasing that plasticity of the ELs may have
implications for the activation of GPCRs. Interestingly, here we
characterized the eﬀects of distinct cis and trans isomers of this
nucleoside on the adenylyl cyclase system. However, the eﬀects
on other eﬀector systems that may be coupled to these
adenosine receptor subtypes are unknown and would not
necessarily follow the same characteristic patterns we revealed.
For instance, it is known that APNEA exerts A2AR-dependent
eﬀects in rat cortical synaptosomes through N-type calcium
channels.26 However, it is not known whether isomers of
MRS5543 would exert diﬀerential eﬀects in that model. Also,
we did not evaluate the eﬀects at the A1 or A2B receptors;
APNEA binds with moderate aﬃnity to the A1 but not to A2B
receptors.27,28 Therefore, although we were able to provide
detailed information on A3R and A2AR activity, it is necessary to
be aware that more work is still needed to elucidate a detailed
understanding of the recognition of cis and trans stereoisomers
of MRS5543 at adenosine receptor subtypes in both activated
and basal states.
In conclusion, we presented here the ﬁrst photochromic
adenosine-based compound, a visible (less harmful) light-
switchable, azobenzene-containing adenosine receptor ligand
whose intrinsic activity is light-moldable. The design strategy
for this compound was facilitated and results interpreted with
the aid of a recently determined X-ray structure of an adenosine
receptor. With the surge of new X-ray structures reported for
GPCRs,36 it seems reasonable that similar approaches could be
used for many other receptors (GPCRs), which are indeed the
mechanistic framework for many of the pharmaceuticals on the
market. Accordingly, our application of ligand photomodulation
to this important class of signaling proteins, demonstrating the
feasibility of modulating metabotropic receptors by small
molecules using light, could serve as a model for a much
broader application of this kind of approach. We envision its
application both in pharmacological tool compounds and
potentially in therapeutic agents toward the goal of achieving a
site- and time-speciﬁc action.
■ EXPERIMENTAL PROCEDURES
Synthesis of MRS5543. All reagents and solvents were
purchased from Sigma-Aldrich (St. Louis, MO, USA). 1H NMR
spectra were obtained with a Bruker 400 spectrometer (Bruker
Corp., Billerica, MA, USA), and chemical shifts are expressed in
δ values (ppm) with tetramethylsilane (δ 0.00). Analytical TLC
was performed using glass sheets precoated with silica gel F254
(0.2 mm) from Sigma-Aldrich. The purity of ﬁnal nucleoside
derivative was shown to be >95% (detection at 254 nm) using a
Hewlett−Packard 1100 HPLC equipped with a Zorbax SB-Aq
5 μm analytical column (50 × 4.6 mm; Agilent Technologies
Inc., Palo Alto, CA, USA). Mobile phase: linear gradient solvent
system, 5 mM TBAP (tetrabutylammonium dihydrogen
phosphate)−CH3CN from 80:20 to 0:100 in 13 min; the
ﬂow rate was 0.5 mL/min. Peaks were detected by UV
absorption with a diode array detector at 230, 254, and 280 nm.
N6-2-(4-{(E)-[4-(Diethylamino)phenyl]diazenyl}phenyl)-
ethyladenosine (MRS5543, 2) was synthesized as follows
(Figure 1). APNEA (10 mg, 25.8 μmol, 1) was dissolved in
hydrochloric acid solution (20% of 12 M hydrochloric acid in
water; 200 μL) and the solution cooled to 0 °C using an ice
bath with vigorous stirring. A solution of sodium nitrite (2.0
mg; 28 μmol) in water (10 μL) was then added and the
solution stirred at 0 °C for 20 min to allow formation of the
diazonium salt to occur (Figure 1, step 1). During this time,
N,N-diethylaniline (5.0 μL; 33 μmol) (Figure 1) dissolved in
methanol (5 μL) and sodium hydroxide (10% soln. in water;
200 μL) (Figure 1, step 2) was cooled to 0 °C. This solution
was then added dropwise to the preformed, cooled diazonium
salt solution in the dark, and the solution was adjusted to
neutrality. The solution was extracted with ethyl acetate (10
mL); the organic layer was separated, washed with saturated
aqueous sodium bicarbonate solution (2 × 10 mL) and brine (1
× 10 mL), dried (MgSO4), and then concentrated under
reduced pressure to give a yellowish brown solid. This solid was
puriﬁed by semipreparative silica gel plate chromatography (5:1
dichloromethane: methanol). Evaporation of the solvents
provided the title compound as a homogeneous yellow solid
(7 mg, 50%). δH (CD3CN): 8.26 (1H, bs), 7.97 (1H, bs), 7.79
(2H, d, J = 9.24 Hz), 7.73 (2H, d, J = 8.4 Hz), 7.42 (2H, d, J =
8.04 Hz), 6.82 (2H, d, J = 9.28 Hz), 5.8 (1H, d, J = 6.88 Hz),
4.82−4.79 (1H, m), 4.32−4.31 (1H, m), 4.16 (1H, m), 3.9
(2H, bm), 3.83−3.79 (1H, m), 3.69−3.64 (1H, m), 3.49 (4H,
q), 3.07 (2H, t), 1.21 (6H, t). HRMS: (MH+) found 547.2781;
C28H35O4N8 requires 547.2759.
Photochemical Characterization of MRS5543. Steady-
state absorption measurements were registered in a UV−vis HP
8453 spectrophotometer (Agilent Technologies, Inc., Colorado
Springs, CO, USA). Transient absorption measurements were
performed by means of a LKII laser ﬂash photolysis
spectrometer (Applied Photophysics, Surrey, UK) equipped
with a Xe lamp, a monochromator, and a photomultiplier
(PMT) tube (Hamamatsu Photonics, Hamamatsu, Japan). The
20 ns pulsed laser beam arising from an Rainbow OPO
(Quantel, Les Ulis, France) pumped by a Nd:YAG Brilliant
laser (Quantel) was used to excite the solutions of interest at
460 nm and 1 mJ/p. The signal from the PMT tube was
collected in a 500 MHz oscilloscope (Agilent Technologies,
Inc.) and transferred to an Accorn PCRisk station. In this way
the decay kinetics of photogenerated transient species at
selected wavelengths could be measured and subsequently
analyzed by means of nonlinear least-squares exponential
ﬁttings.
Plasmid Constructs. The use of the A2AR
Rluc was
previously described,29 and the A3R
Rluc construct was obtained
using standard molecular biology techniques and the cDNA
encoding the human A3R gene as a template.
30 Brieﬂy, the
human A3R sequence was ampliﬁed using the sense
oligonucleotide primer FA3XhoI (5′-CGGCTCGAGATG-
CCCAACAACAGCACTGCTC-3′) and the antisense primer
RA3BamHI (5′-GCGGGATCCCGCTCAGAATTCTTC-
TCAATGCTTGTGTCC-3′). The fragment was then subcl-
oned in-frame into the XhoI/BamHI sites of the pRluc-N1
(Packard Bioscience, Madrid, Spain), resulting in the A3R with
Renilla luciferase at its C-terminus (A3R
Rluc). All constructs
were veriﬁed by nucleotide sequencing.
Cell Culture and Transfection. Human embryonic kidney
(HEK-293T) cells were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Sigma-Aldrich) supplemented with 1 mM
sodium pyruvate, 2 mM L-glutamine, 100 μg/mL streptomycin,
100 U/mL penicillin, and 5% (v/v) fetal bovine serum at 37 °C
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and in an atmosphere of 5% CO2. Cells were transiently
transfected with TransFectin Lipid Reagent (Bio-Rad Labo-
ratories, Hercules, CA, USA).
MTT Viability Assay. The impact of MRS5543 treatment
and 460 nm irradiation on cell viability was examined by MTT
assay. In brief, HEK-293T cells were grown in 96-well plates for
24 h. Cells were treated during 2 h with increasing
concentrations of MRS5543 with and without irradiation at
460 nm by using a custom-made 9 × 4 light-emitting diode
(LED) matrix (12 × 9 cm) (FCTecnics, Barcelona, Spain)
installed in the culture hood at height of 2 cm above the cells.
Subsequently, the cells were washed and incubated for 2 h in
the dark at 37 °C with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich). Follow-
ing the lysis of the cells the cell viability was determined by
measuring the absorbance at 560 nm. Interestingly, the
MRS5543 treatment (ranging from 10 nM to 3.3 μM) did
not aﬀect the cell viability in either dark or upon 460 nm
irradiation conditions (Supporting Information Figure 1).
cAMP Assay. We used a dual luciferase reporter assay to
indirectly detect variations of cAMP levels in transiently
transfected HEK-293T cells. Accordingly, cells were seeded at
a density of 1 × 106 cells/well in 6-well dishes, and co-
transfected with 2 μg of the plasmid encoding the cAMP
response element−ﬁreﬂy luciferase fusion protein (pGL4-CRE-
luc2p; Promega, Madison, WI, USA) plus 2 μg of plasmid
encoding either A2AR
Rluc or A3R
Rluc, approximately 36 h after
transfection and then treatment with the indicated ligand
during 2 h in the presence of 50 μM zardaverine and with and
without irradiation at 460 nm. Cells were then harvested,
washed twice with PBS, and the ﬁreﬂy luciferase luminescence
(FLU) determined using the Bright-Glo luciferase assay system
(Promega) following the manufacture’s indications. The Renilla
luciferase luminescence (RLU) was determined by incubating
the cells with 5 μM of benzyl-coelenterazine (NanoLight
Technology, Pinetop, AZ, USA).31 Both ﬁreﬂy and Renilla
luminescence was measured in a POLARstar Optima plate
reader (BMG Labtechnologies, Ortenberg, Germany) using a
30 nm bandwidth 535 nm ﬁlter setting. The ﬁreﬂy luciferase
activity was normalized against Renilla luciferase values (i.e.,
FLU/RLU) for each data point.
Statistics. The number of samples (n) in each experimental
condition is indicated in the ﬁgure legends. The statistical
analysis was performed by two-way analysis of variance
(ANOVA) followed by Bonferroni posthoc test. Statistical
signiﬁcance was set as P < 0.05.
Molecular Modeling. The adenosine derivatives (prepared
for docking using the build panel and the LigPrep panel
implemented in the Schrödinger suite)32 were docked in an
agonist-bound structure of the human A2AR (PDB code
3QAK)17 and in a model of the closely related human A3R.
More precisely, a model of the hA2AR was built, using the
homology modeling tool implemented in the MOE suite,33 to
ﬁll the portion of EL2 that is missing in the crystal (from
Gly142 to Leu167). Coordinates for these residues were taken
from another agonist-bound hA2AR crystal structure (PDB code
2YDV).19 The human A3R homology model was built using
MOE suite,33 as previously reported,18,34 based on the human
A2AR structure
17 as a template.
Glide35 module of the Schrödinger suite was used for the
docking in the rigid binding site using the SP (standard
precision) procedure. A Glide Grid was centered within key
conserved residues of the binding pocket, i.e., Phe (EL2), Asn
(6.55), Trp (6.48), and His (7.43). The Glide Grid was built
using an inner box (ligand diameter midpoint box) of 6 Å × 6
Å × 14 Å and an outer box that extended 20 Å in each direction
from the inner one. The top scoring docking poses for each
ligand were subjected to visual inspection and analysis of
protein−ligand interactions to select the proposed binding
conformations.
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